What You Should Know:
- physIQ has been selected by the National Institute of Health (NIH) to develop an innovative AI-based COVID-19 digital biomarker solution to address the COVID-19 pandemic.
- Early detection of COVID-19 decompensation in patients
is complicated by infrequent and non-specific clinical data. The first-in-kind
tool will collect and analyzes continuous physiologic data could provide early
clinical indicators of COVID-19 decompensation.
The National Cancer
Institute
Read More
Biosensors in Healthcare | Devices | Analytics | News, Analysis, Insights
HHS Launches $1.5M Second Phase of KidneyX Prize Competition to Redesign Dialysis
- KidneyX launches the $1.5 million second phase of the Redesign Dialysis prize competition.- Redesign Dialysis Phase 2 seeks prototype solutions or components of solutions, that can replicate normal kidney functions or improve dialysis access.- The competition calls on researchers, innovators, patients, and investors with expertise in nephrology, biotechnology, bioengineering, and medical devices to submit solutions.The U.S. Department of Health and Human Services (HHS) and the American Society
Read More
Research: Microneedle Biosensors Accurately Detect Patient’s Antibiotic Levels in Real-Time
- Researchers find microneedle biosensors can be used to monitor the changing concentration of antibiotics in a patient’s system.
- Findings published in The Lancet Digital Health, show the sensors enable real-time monitoring of changes in antibiotic concentration in the body, with similar results to those obtained from blood tests.
Small, non-invasive patches worn on the skin can accurately detect the levels of medication in a patient's system, matching the accuracy of current
Read More
Mercy Virtual Integrates With AI Health Monitoring Platform Myia Health
- Mercy Virtual integrates with intelligent health monitoring platform Myia Health to accelerate the adoption of new patient care and at-risk reimbursement models.
- Myia is a digital health platform that collects biometric data from curated sensors, including best in the market and over the counter, Apple and Fitbit.
- Mercy Ventures, Mercy’s corporate venture capital group leads $10M Series A funding investment in Myia to further strengthen the partnership.
Myia Health,
Read More
Yale, Mayo Clinic, Biofourmis Launches Research to Detect Heart Failure Using Wearable Biosensor Data
Biofourmis has entered a research partnership with the Yale University-Mayo Clinic Center of Excellence in Regulatory Science and Innovation (CERSI). Biofourmis' mobile platform BiovitalsHFTM will be leveraged in a study of patients with heart failure to monitor functional capacity and quality of life to see if greater emphasis should be placed on these measures in the drug approval process.Impact of Heart FailureHeart failure afflicts approximately 6.5 million patients in the United States and
Read More
Study: Fitbit Devices Could Predict Inflammatory Bowel Disease (IBD) Flare-Ups
Fitbit devices could help predict the flare-ups of inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, according to a new study published in the Journal of Crohn's and Colitis. The year-long study, which was recently presented at Digestive Disease Week, was conducted by the University of Chicago.Impact of IBD Flare-UpsEven when managed well, IBD can flare up or cause symptoms unexpectedly, which may be triggered by diet, stress, and physical activity (or lack
Read More
Healthcare M&A Survey: Health IT Represents the Richest Opportunity in Sector
Most healthcare mergers and acquisitions (M&A) professionals see a positive outlook for healthcare and life sciences deals next year, even as political uncertainty will be the biggest factor to upend transactions, according to a recent Merrill Insight poll of global M&A professionals.According to the poll, which included more than 200 respondents from the Americas and Europe, the Middle East and Africa (EMEA), 52% of respondents believe that the M&A market is headed in a positive
Read More
Biofourmis Lands $35M for AI-Powered Digital Therapeutics Platform
Biofourmis, a Boston, MA-based digital therapeutics platform, today announced that it has raised $35 million in Series B funding led by Sequoia Capital/Sequoia India and co-led by Mass Mutual. The latest funding round will enable the company to advance its proprietary artificialintelligence (AI)-powered digital therapeutics platform and pipeline that treats and manages a range of complex chronic conditions.Digital Therapeutics is Redefining The Healthcare Value ChainFounded in 2015, Biofourmis
Read More
5 Disruptive Technologies Driving The Future of Patient Monitoring Solutions
The patient monitoring market is expected to be worth more than $350 billion by 2025, as the focus is likely to move beyond device
sales to solutions, according to a recent Frost & Sullivan's report.
The report, Patient
Monitoring Industry—Analysis of Investment and Trends outlines the
future of patient monitoring across the continuum of care, the shifts in the
market, and investment opportunities.
Evolution of
Patient Monitoring
Patient monitoring has evolved from
Read More
Biolinq Lands $4.75M to Expand Biosensor Patch for Continuous Glucose Monitoring
Biolinq, a San Diego, CA-based digital health company developing a minimally-invasive electrochemical biosensor patch for continuous glucose monitoring (CGM) has raised $4.75 million in Series A funding led by the JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners. Existing investors in the round include M Ventures and Hikma Ventures, the corporate venture capital arm of Hikma Pharmaceuticals. The latest round brings Biolinq’s total Series A funding to $15 million.Inception of
Read More
